Google DeepMind’s Demis Hassabis speaks at the 2026 Google I/O Technology Developer Conference in Mountain View, California on May 19, 2026.
Carl Mondon | AFP | Getty Images
Isomorphic Labs, the artificial intelligence drug discovery startup founded by former Google DeepMind chief Demis Hassabis, has raised $5 billion in Series C funding, the company announced Tuesday.
Isomorphic’s round comes three and a half months after Hassabis stepped down as CEO of Google’s AI lab DeepMind, which he co-founded before being acquired by the big tech giant in 2014.
The round was co-led by Greenoaks and Sequoia Capital along with Andreessen Horowitz, with investments in: alphabetGoogle’s parent company. The new funding will help fund the design and development of new drugs using AI.
Investors are pouring record amounts of money into drug discovery startups in 2026 as companies look to take advantage of advances in AI. OpenAI and Anthropic are also investing in tools to develop new drugs using this technology.
Hassabis has been CEO of Isomorphic Labs since the startup spun out of DeepMind in 2021.
“When we founded Isomorphic, we believed that biology can be understood and modeled at the most fundamental molecular level, and that it can be fundamentally accelerated through AI,” Hassabis said.
“This round will enable us to accelerate our progress by building fundamental biological models, deepening our understanding of systemic disease, and advancing first treatment programs toward clinical trials that have a tangible impact on patients,” he added.
Isomorphic has built a proprietary drug design engine and treatment candidate pipeline designed using AI, which the company says will help deliver next-generation medicines.
Anthropic announced the launch of an AI drug discovery program in June, and OpenAI partnered with Novo Nordisk in April.
According to deal aggregation platform Dealroom, drug discovery startups will raise $23.2 billion in 2026, a record number.
Isomorphic last raised funding in May, raising $2.1 billion in Series B.
